CSL Of Australia Faces U.S. University In Plasma Class-Action Suit
This article was originally published in PharmAsia News
Executive Summary
Australia's CSL faces an additional foe in an expanding blood-plasma class-action suit, this one a U.S. university claiming damages. The University of Utah joined the class-action suit in a U.S. district court, seeking $10 million from CSL, its CSL Behring unit and Baxter International, CSL's main competitor in the United States. The university is the first educational institution to join the suit filed by several U.S. hospitals claiming the company conspired with other plasma companies to rig markets and plasma supplies. (Click here for more
You may also be interested in...
Changes To EU Pharma Reform: More Questions Than Answers?
In the first of a series of articles on the future direction of the EU pharmaceutical reform proposals, the Pink Sheet looks at the new uncertainties created for the drug industry after the European Parliament voted through a series of amendments in the area of regulatory data protection.
Probiotics And Cold Remedies Boost Recordati In 2023
Italy's Recordati saw its OTC sales grow by 10% in 2023 driven by the recovery of the cough & cold market and a growing demand for probiotics.
Falling Sales Force New Priorities At Roche
The Swiss major brings a new ruthlessness to the compounds in its pipeline: if they’re not first or best, they’re out.